Beam Therapeutics Q1 net loss narrows to $94.3 million from $108.3 million
Beam Therapeutics reported first quarter 2026 results, with a net loss of $94.3 million, or $0.91 per share, compared with $108.3 million, or $1.23 per share, a year earlier. License and collaboration revenue rose to $31.7 million from $7.5 million, and the company ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities, which it says will fund operations into mid-2029.
Key points
- Net loss was $94.3 million, or $0.91 per share, for the quarter ended March 31, 2026, versus $108.3 million, or $1.23 per share, a year earlier.
- License and collaboration revenue was $31.7 million, up from $7.5 million in the first quarter of 2025.
- R&D expenses were $104.5 million and G&A expenses were $34.4 million, compared with $98.8 million and $27.9 million a year earlier.
- Cash runway is expected to support operations into mid-2029, including $100 million from the Sixth Street financing agreement and an anticipated additional $100 million from the Sixth Street facility.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.